Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
|
SELLAS Life Sciences Group, Inc. (SLS)
|
Add to portfolio |
|
|
|
| Price: |
$8.45
| | Metrics |
| OS: |
28.3
|
M
| |
-745
|
% ROE
|
| Market cap: |
$240
|
M
| |
|
|
|
Net cash:
|
$13.8
|
M
| |
$0.49
|
per share
|
|
EV:
|
$226
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($36.7)
|
M
| |
|
|
|
EBIT
|
($36.7)
|
M
| |
|
|
| EPS |
($1.59)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 1.0 | 7.6 | 1.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -86.8% | 300.0% | | | | | | |
| Cost of goods sold | 0.1 | 0.2 | 0.0 | 0.0 | -31.1 | -45.6 | 0.0 | 0.0 |
| Gross profit | 0.9 | 7.4 | 1.9 | 0.0 | 31.1 | 45.6 | 0.0 | 0.0 |
| Gross margin | 90.0% | 97.4% | 100.0% | | | | | |
| Selling, general and administrative | 12.6 | 11.3 | 9.6 | 9.9 | 12.8 | 15.1 | 4.6 | |
| Research and development | 20.3 | 15.7 | 9.3 | 7.3 | 8.8 | 6.1 | 11.4 | 23.6 |
| General and administrative | | | | | | | | 10.6 |
| EBITA | -31.7 | -15.3 | -16.7 | -17.8 | 12.9 | 2.3 | -16.0 | -39.5 |
| EBITA margin | -3165.4% | -200.8% | -879.1% | | | | | |
| Amortization of intangibles | | | | | | 1.9 | | |
| EBIT | -31.7 | -15.3 | -16.7 | -17.8 | 12.9 | 0.5 | -16.0 | -39.5 |
| EBIT margin | -3165.4% | -200.8% | -879.1% | | | | | |
| Pre-tax income | -41.3 | -20.9 | -16.8 | -19.4 | -29.0 | -23.5 | -17.7 | -38.6 |
| Income taxes | 0.0 | -0.2 | 0.0 | -0.1 | -1.4 | 0.3 | 0.0 | 0.4 |
| Tax rate | 0.0% | 1.1% | 0.1% | 0.4% | 4.7% | | | |
| Net income | -41.3 | -20.7 | -16.8 | -28.0 | -41.3 | -24.4 | -17.7 | -63.9 |
| Net margin | -4130.0% | -272.4% | -886.1% | | | | | |
| |
| Diluted EPS | ($2.13) | ($1.34) | ($2.11) | ($10.92) | ($157.72) | ($10.44) | ($18.66) | ($5.02) |
| Shares outstanding (diluted) | 19.4 | 15.5 | 8.0 | 2.6 | 0.3 | 2.3 | 0.9 | 7.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|